Dedicated to Conquering Heart Failure
A clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular diseases
Acute Myocarditis
Cardiol has received IND authorization from the U.S FDA to conduct a Phase II multi-national trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis – an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age.
Learn More
Recurrent Pericarditis
Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis – the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.
Learn More
Viral Infection and CVD
CardiolRx™ is currently being evaluated in a Phase II/III multi-national study, the LANCER trial, to evaluate its safety and efficacy as a cardioprotective therapy to reduce major cardiorespiratory events and improve symptoms in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the impact of CardiolRx™ on key cardiac and inflammatory biomarkers.
Learn More
Heart Failure
Cardiol is developing a subcutaneous cannabidiol formulation targeting the inflammation and fibrosis associated with the development and progression of heart failure – a chronic condition estimated to affect 64 million globally and is a leading cause of death and hospitalization, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.
Learn More
LATEST NEWS
All News
Press Release
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
October 03, 2022
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx™ Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
Press Release
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
Press Release
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis
August 03, 2022
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx™ for Treatment of Acute Myocarditis
TSX:CRDL NASDAQ:CRDL
